Clinical trials: Patients at Risk for Thrombosis
Venous Thromboembolism, Venous Thrombosis
Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
The aim of the study is to evaluate efficacy and safety of venous thromboembolism prophylaxis by the combination of graduated compression stockings (GCS), standard doses of low-molecular-weight heparins (LMWH) and sequential…
- Trial name
- IPCSUPER (NCT03044574)
- Testing
- SCD, GCS, LMWH
- Where
- 2 sites in Russia
- Volunteers
- 407 people
- Sponsor
- Pirogov Russian National Research Medical University
Obesity, Venous Thrombosis
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
Deep vein thrombosis(DVT) is a common complication in hospitalized medical patients. Consensus guidelines recommend using medications such as heparin or low-molecular-weight heparins (LMWH) to prevent DVT in these patients.
- Conditions
- Obesity, Venous Thrombosis, Anticoagulants
- Trial name
- NCT00585182
- Testing
- Enoxaparin 0.5 mg/kg once daily
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Utah
Bleeding, Thrombosis
Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery
Patients who have undergone placement of coronary stents require dual antiplatelet therapy with Plavix and aspirin to prevent the serious complication of in-stent thrombosis.
- Trial name
- NCT00653601
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke
Registry on WATCHMAN Outcomes in Real-Life Utilization
The WATCHMAN LAA Closure Technology is designed to prevent embolization of thrombi that may form in the LAA, thereby preventing the occurrence of ischemic stroke and systemic thromboembolism.
- Trial name
- EWOLUTION (NCT01972282)
- Testing
- WATCHMAN Left Atrial Appendage Closure
- Where
- 47 sites in Belgium, France and 11 more
- Volunteers
- 1,025 people
- Sponsor
- Boston Scientific Corporation